PLIVA Announces Approval for Citalopram Hydrobromide Tablets
PLIVA d.d. announced today that PLIVA has received final approval from the U.S. Food and Drug Administration (“FDA”) for its Abbreviated New Drug Application (“ANDA”) for Citalopram Hydrobromide Tablets 10 mg, 20 mg, and 40 mg.
Citalopram Hydrobromide is the AB-rated generic equivalent of Forest Laboratories’ Celexa, from a class of medications called selective serotonin reuptake inhibitors (SSRIs), used for the treatment of depression.
More information about PLIVA can be found at www.pliva.com.
For additional information, please contact:
Investor Relations & Corporate Communications
Tel: +385 1 6160 355, 6120 909
Fax: +385 1 6114 413
This release contains certain "forward-looking statements", relating to the Group's business, which can be identified by the use of forward-looking terminology such as "will", "planned", "expectations", "forecast" or similar expressions, or by discussions of strategy, plans or intentions. Such statements include descriptions of new products expected to be introduced or have been introduced by the Group companies and anticipated customer demand for such products. Such statements reflect the current views of the Group with respect to future events and are subject to certain risks, uncertainties and assumptions. Many factors could cause the actual results, performance or achievements of the Group to be materially different from any future results that may be expressed or implied by such forward-looking statements.
- 2005-11-03 PR Citalopram US Approval.pdf ( 64,3 KB)